Ambrx Biopharma Inc. (AMAM)
28.00
0.02 (0.07%)
At close: Mar 06, 2024, 9:00 PM
0.07% (1D)
| Bid | n/a |
| Market Cap | 1.77B |
| Revenue (ttm) | 3.44M |
| Net Income (ttm) | -69.37M |
| EPS (ttm) | 0.42 |
| PE Ratio (ttm) | 66.66666666666667 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,422,420 |
| Avg. Volume (20D) | 1,943,941 |
| Open | 27.99 |
| Previous Close | 27.98 |
| Day's Range | 27.98 - 28.00 |
| 52-Week Range | 6.55 - 28.15 |
| Beta | -2.36 |
About AMAM
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical tri...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 14, 2023
Employees 87
Stock Exchange NYSE
Ticker Symbol AMAM
Website https://ambrx.com